Reprogramming the future: Capitalizing on in vitro embryo culture by advancing stem cell technologies in the fight against rare genetic disorders

Lisha Li; Taiwei Zhang; Zhaozhao Hua; Jing Wang; Hongmei Sun; Qian Chen; Yiyuan Zhou; Ling Wang

doi:10.5582/irdr.2023.01074

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Reprogramming the future: Capitalizing on in vitro embryo culture by advancing stem cell technologies in the fight against rare genetic disorders

Lisha Li, Taiwei Zhang, Zhaozhao Hua, Jing Wang, Hongmei Sun, Qian Chen, Yiyuan Zhou, Ling Wang

著者情報

Lisha Li
Laboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
The Academy of Integrative Medicine of Fudan University, Shanghai, China.
Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China.
Taiwei Zhang
Research Center of Obstetrical Eugenics, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China.
Zhaozhao Hua
Department of Obstetrics, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China.
Jing Wang
Laboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
The Academy of Integrative Medicine of Fudan University, Shanghai, China.
Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China.
Hongmei Sun
Laboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
The Academy of Integrative Medicine of Fudan University, Shanghai, China.
Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China.
Qian Chen
Research Center of Obstetrical Eugenics, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China.
Yiyuan Zhou
Research Center of Obstetrical Eugenics, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China.
Ling Wang
Laboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
The Academy of Integrative Medicine of Fudan University, Shanghai, China.
Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China.

キーワード: embryo engineering, reproductive genetics, genetic disorders, stem cell therapies, ethical balance

ジャーナルフリー早期公開

論文ID: 2023.01074

DOI https://doi.org/10.5582/irdr.2023.01074

この記事には本公開記事があります。

The final version of this article is now available: Vol. 13 (2024), No. 2 pp. 117-120

詳細

抄録

Capitalizing on breakthroughs in reproductive genetics, the utilization of in vitro embryo culture and stem cell technologies heralds a transformative era in addressing global challenges posed by rare genetic diseases. These cutting-edge practices illuminate the intricacies of early human development, elucidate the mechanisms behind rare diseases, and guide the development of potential therapies. Balancing this remarkable innovation with necessary ethical considerations, these technologies have the potential to revolutionize the trajectory of rare genetic disorders, transforming the landscape of diagnosis, treatment, and genetic counseling while offering renewed hope for affected individuals and families worldwide.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）